Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion
By LabMedica International staff writers Posted on 25 Feb 2015 |
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).
A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which encodes the fusion protein mitofusin 2.
Despite the established role of mitofusins (Mfn1 and Mfn2) in mitochondrial fusion, only Mfn2 had been associated with metabolic and neurodegenerative diseases, which suggests that this protein is needed to maintain mitochondrial energy metabolism. Mice lacking the MFN1 gene, which encodes mitofusin 1, seem perfectly healthy, but MFN2-deficient mice die soon after birth. Furthermore, mutations in the MFN2 gene cause human diseases, including the peripheral neuropathy Charcot-Marie-Tooth type 2A. The molecular basis for the mitochondrial dysfunction encountered in the absence of Mfn2 has not been explained.
In the current study, investigators at the Max Planck Institute for Biology of Ageing (Cologne, Germany) worked with cultures of mouse heart muscle cells lacking the MFN2 gene.
They reported in the February 16, 2015, online edition of the Journal of Cell Biology that energy metabolism in the cells was impaired compared to that of healthy heart cells or of heart cells that lacked only Mfn1. The energy metabolic process in the Mfn2-deficient cells was found to have been disrupted by reduced levels of coenzyme Q, a key component of the mitochondrial respiratory chain that generates cellular energy in the form of ATP.
The reduced respiratory chain function in the mitochondria of cells lacking Mfn2 could be partially restored by supplementation with coenzyme Q10, which suggested a possible therapeutic strategy for patients with diseases caused by mutations in the MFN2 gene.
Related Links:
Max Planck Institute for Biology of Ageing
Despite the established role of mitofusins (Mfn1 and Mfn2) in mitochondrial fusion, only Mfn2 had been associated with metabolic and neurodegenerative diseases, which suggests that this protein is needed to maintain mitochondrial energy metabolism. Mice lacking the MFN1 gene, which encodes mitofusin 1, seem perfectly healthy, but MFN2-deficient mice die soon after birth. Furthermore, mutations in the MFN2 gene cause human diseases, including the peripheral neuropathy Charcot-Marie-Tooth type 2A. The molecular basis for the mitochondrial dysfunction encountered in the absence of Mfn2 has not been explained.
In the current study, investigators at the Max Planck Institute for Biology of Ageing (Cologne, Germany) worked with cultures of mouse heart muscle cells lacking the MFN2 gene.
They reported in the February 16, 2015, online edition of the Journal of Cell Biology that energy metabolism in the cells was impaired compared to that of healthy heart cells or of heart cells that lacked only Mfn1. The energy metabolic process in the Mfn2-deficient cells was found to have been disrupted by reduced levels of coenzyme Q, a key component of the mitochondrial respiratory chain that generates cellular energy in the form of ATP.
The reduced respiratory chain function in the mitochondria of cells lacking Mfn2 could be partially restored by supplementation with coenzyme Q10, which suggested a possible therapeutic strategy for patients with diseases caused by mutations in the MFN2 gene.
Related Links:
Max Planck Institute for Biology of Ageing
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples